P08.21 * the Role of Targeted Therapy in Complex Treatment of Patients With Brain Metastases (Bm) From Renal Cell Cancer (Rcc)

Abstract

BACKGROUND: About 2-11% of all patients (pts) with RCC develop BM, leading to a poor prognosis and a median survival of ,6 months after whole brain radiotherapy. This study was designed to evaluate targeted therapy in RCC pts with BM. METHODS: Eligible pts had confirmed RCC and BM (≥1 lesion of ≥10mm diameter) aged .18 years with ECOG performanse status (PS) of 0-2. From